All other terms and conditions of the offer remain unchanged, Roche said in a statement on Friday.

"Based on conversations with Genentech shareholders, we believe that there is a strong sentiment to bring this process to a conclusion," Chairman Franz Humer said in the statement.

Roche is bidding to buy the 44 percent of Genentech it does not already own, with the raised offer valuing the stake at $45.7 billion, the company said.

"As a result, we are increasing our price to $93 per share to maximize shareholder participation and will proceed quickly to complete all necessary financing. We now look forward to successfully completing the transaction," Humer said.

(Reporting by Sam Cage; Editing by Greg Mahlich)